Insulin Glargine - European Medicines Agency Update On Safety
Main Category: DiabetesAlso Included In: Regulatory Affairs / Drug Approvals
Article Date: 27 Jul 2009 - 2:00 PDT
email to a friend 
printer friendly 
opinions
| Patient / Public: |  |
1 (1 votes) |
| Healthcare Prof: |  |
3.67 (3 votes) |
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that there is no cause for concern of the risk of cancer for people with diabetes on insulin glargine (Lantus).
In June, studies published in 'Diabetologia', the Journal of the European Association for the Study of Diabetes, suggested there may be a small increased risk of cancer in those taking glargine as their only insulin.
The CHMP carried out an in-depth review of these studies and their outcomes. The studies were found to be inconclusive. In addition, the committee noted that the results of the studies were not consistent.
Source
Diabetes UK
Visit our diabetes section for the latest news on this subject.
MLA
12 Feb. 2012. <http://www.medicalnewstoday.com/releases/158882.php>
APA
http://www.medicalnewstoday.com/releases/158882.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Privacy Policy |
Terms and Conditions
MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
